25 XP   0   0   10

DiaMedica Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Diamedica together

PenkeI guess you are interested in DiaMedica Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of DiaMedica Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about DiaMedica Therapeutics Inc

I send you an email if I find something interesting about DiaMedica Therapeutics Inc.

Quick analysis of Diamedica (30 sec.)










What can you expect buying and holding a share of Diamedica? (30 sec.)

How much money do you get?

How much money do you get?
$0.97
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$1.35
Expected worth in 1 year
$1.85
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$1.48
Return On Investment
60.4%

For what price can you sell your share?

Current Price per Share
$2.45
Expected price per share
$2.05 - $3.2
How sure are you?
50%

1. Valuation of Diamedica (5 min.)




Live pricePrice per Share (EOD)

$2.45

Intrinsic Value Per Share

$-3.94 - $-2.56

Total Value Per Share

$-2.60 - $-1.21

2. Growth of Diamedica (5 min.)




Is Diamedica growing?

Current yearPrevious yearGrowGrow %
How rich?$51m$36.3m$12m24.8%

How much money is Diamedica making?

Current yearPrevious yearGrowGrow %
Making money-$4.8m-$3.4m-$1.4m-29.4%
Net Profit Margin0.0%-7,463.9%--

How much money comes from the company's main activities?

3. Financial Health of Diamedica (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#471 / 1010

Most Revenue
#999 / 1010

Most Profit
#420 / 1010

Most Efficient
#445 / 1010

What can you expect buying and holding a share of Diamedica? (5 min.)

Welcome investor! Diamedica's management wants to use your money to grow the business. In return you get a share of Diamedica.

What can you expect buying and holding a share of Diamedica?

First you should know what it really means to hold a share of Diamedica. And how you can make/lose money.

Speculation

The Price per Share of Diamedica is $2.45. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Diamedica.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Diamedica, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.35. Based on the TTM, the Book Value Change Per Share is $0.13 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.08 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.24 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Diamedica.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.14-5.5%-0.13-5.2%-0.09-3.7%-0.09-3.7%-0.06-2.6%
Usd Book Value Change Per Share-0.12-4.9%0.135.2%-0.08-3.3%0.041.8%0.031.3%
Usd Dividend Per Share0.000.0%0.249.9%0.000.0%0.052.0%0.021.0%
Usd Total Gains Per Share-0.12-4.9%0.3715.1%-0.08-3.3%0.093.8%0.062.3%
Usd Price Per Share2.84-2.82-1.84-4.02-2.19-
Price to Earnings Ratio-5.22--5.65--5.08--11.68--8.21-
Price-to-Total Gains Ratio-23.58--14.28--22.64--42.09--39.94-
Price to Book Ratio2.11-2.19-1.90-7.92-37.48-
Price-to-Total Gains Ratio-23.58--14.28--22.64--42.09--39.94-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.45
Number of shares408
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.240.05
Usd Book Value Change Per Share0.130.04
Usd Total Gains Per Share0.370.09
Gains per Quarter (408 shares)151.0538.17
Gains per Year (408 shares)604.21152.66
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
13982075948073143
27954131198159146296
311936201802239219449
415908272406318293602
5198810333010398366755
6238512403614477439908
72783144742185575121061
83180165448226365851214
93578186054267166581367
103975206760307957321520

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.069.00.00.0%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%13.027.00.032.5%23.046.00.033.3%
Dividend per Share1.00.03.025.0%1.00.011.08.3%1.00.019.05.0%1.00.039.02.5%1.00.068.01.4%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%13.027.00.032.5%23.046.00.033.3%

Fundamentals of Diamedica

About DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company develops treatments for neurological disorders and cardio-renal disease. Its lead candidate is DM199, a pharmaceutically active recombinant form of the kallikrein-1 protein for the treatment of acute ischemic stroke and other vascular diseases. It is also developing DM300 that is in preclinical stage of development for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Fundamental data was last updated by Penke on 2024-04-11 06:07:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of DiaMedica Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Diamedica earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Diamedica to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of DiaMedica Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-7,463.9%+7,463.9%
TTM-5Y-1,492.8%+1,492.8%
5Y-1,492.8%10Y-23.0%-1,469.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--200.1%+200.1%
TTM--216.8%+216.8%
YOY-7,463.9%-288.3%-7,175.6%
5Y-1,492.8%-449.1%-1,043.7%
10Y-23.0%-605.5%+582.5%
1.1.2. Return on Assets

Shows how efficient Diamedica is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Diamedica to the Biotechnology industry mean.
  • -9.5% Return on Assets means that Diamedica generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of DiaMedica Therapeutics Inc:

  • The MRQ is -9.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.5%TTM-10.5%+0.9%
TTM-10.5%YOY-9.0%-1.5%
TTM-10.5%5Y-13.7%+3.2%
5Y-13.7%10Y-51.2%+37.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.5%-13.3%+3.8%
TTM-10.5%-12.8%+2.3%
YOY-9.0%-11.7%+2.7%
5Y-13.7%-13.9%+0.2%
10Y-51.2%-15.7%-35.5%
1.1.3. Return on Equity

Shows how efficient Diamedica is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Diamedica to the Biotechnology industry mean.
  • -10.1% Return on Equity means Diamedica generated $-0.10 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of DiaMedica Therapeutics Inc:

  • The MRQ is -10.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -11.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.1%TTM-11.3%+1.2%
TTM-11.3%YOY-9.5%-1.8%
TTM-11.3%5Y-14.9%+3.7%
5Y-14.9%10Y-677.6%+662.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.1%-16.9%+6.8%
TTM-11.3%-16.1%+4.8%
YOY-9.5%-15.1%+5.6%
5Y-14.9%-19.3%+4.4%
10Y-677.6%-20.2%-657.4%

1.2. Operating Efficiency of DiaMedica Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Diamedica is operating .

  • Measures how much profit Diamedica makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Diamedica to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of DiaMedica Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-7,498.2%+7,498.2%
TTM-5Y-1,499.6%+1,499.6%
5Y-1,499.6%10Y881.4%-2,381.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM--232.5%+232.5%
YOY-7,498.2%-298.2%-7,200.0%
5Y-1,499.6%-492.1%-1,007.5%
10Y881.4%-632.4%+1,513.8%
1.2.2. Operating Ratio

Measures how efficient Diamedica is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of DiaMedica Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY149.964-149.964
TTM-5Y29.993-29.993
5Y29.99310Y3.584+26.408
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.231-3.231
TTM-3.310-3.310
YOY149.9643.890+146.074
5Y29.9935.739+24.254
10Y3.5847.876-4.292

1.3. Liquidity of DiaMedica Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Diamedica is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 19.27 means the company has $19.27 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of DiaMedica Therapeutics Inc:

  • The MRQ is 19.266. The company is very able to pay all its short-term debts. +2
  • The TTM is 18.266. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ19.266TTM18.266+0.999
TTM18.266YOY23.535-5.269
TTM18.2665Y18.113+0.154
5Y18.11310Y10.170+7.943
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ19.2663.890+15.376
TTM18.2664.173+14.093
YOY23.5355.344+18.191
5Y18.1136.126+11.987
10Y10.1706.448+3.722
1.3.2. Quick Ratio

Measures if Diamedica is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Diamedica to the Biotechnology industry mean.
  • A Quick Ratio of 36.47 means the company can pay off $36.47 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of DiaMedica Therapeutics Inc:

  • The MRQ is 36.474. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 34.155. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ36.474TTM34.155+2.319
TTM34.155YOY44.297-10.142
TTM34.1555Y32.291+1.864
5Y32.29110Y17.224+15.066
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ36.4743.514+32.960
TTM34.1553.998+30.157
YOY44.2975.380+38.917
5Y32.2916.105+26.186
10Y17.2246.404+10.820

1.4. Solvency of DiaMedica Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Diamedica assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Diamedica to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.06 means that Diamedica assets are financed with 5.7% credit (debt) and the remaining percentage (100% - 5.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of DiaMedica Therapeutics Inc:

  • The MRQ is 0.057. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.061. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.057TTM0.061-0.004
TTM0.061YOY0.050+0.011
TTM0.0615Y0.070-0.009
5Y0.07010Y1.163-1.093
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0570.339-0.282
TTM0.0610.336-0.275
YOY0.0500.271-0.221
5Y0.0700.366-0.296
10Y1.1630.389+0.774
1.4.2. Debt to Equity Ratio

Measures if Diamedica is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Diamedica to the Biotechnology industry mean.
  • A Debt to Equity ratio of 6.1% means that company has $0.06 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of DiaMedica Therapeutics Inc:

  • The MRQ is 0.061. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.066. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.061TTM0.066-0.005
TTM0.066YOY0.053+0.012
TTM0.0665Y0.076-0.011
5Y0.07610Y5.825-5.749
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0610.388-0.327
TTM0.0660.402-0.336
YOY0.0530.335-0.282
5Y0.0760.426-0.350
10Y5.8250.461+5.364

2. Market Valuation of DiaMedica Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Diamedica generates.

  • Above 15 is considered overpriced but always compare Diamedica to the Biotechnology industry mean.
  • A PE ratio of -5.22 means the investor is paying $-5.22 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of DiaMedica Therapeutics Inc:

  • The EOD is -4.505. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.222. Based on the earnings, the company is expensive. -2
  • The TTM is -5.652. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.505MRQ-5.222+0.717
MRQ-5.222TTM-5.652+0.430
TTM-5.652YOY-5.079-0.573
TTM-5.6525Y-11.684+6.031
5Y-11.68410Y-8.208-3.476
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.505-2.264-2.241
MRQ-5.222-2.629-2.593
TTM-5.652-2.680-2.972
YOY-5.079-4.145-0.934
5Y-11.684-6.257-5.427
10Y-8.208-6.254-1.954
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of DiaMedica Therapeutics Inc:

  • The EOD is -6.490. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.523. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.902. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.490MRQ-7.523+1.033
MRQ-7.523TTM-5.902-1.621
TTM-5.902YOY-6.004+0.102
TTM-5.9025Y-15.956+10.054
5Y-15.95610Y-9.519-6.437
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.490-2.973-3.517
MRQ-7.523-3.333-4.190
TTM-5.902-3.553-2.349
YOY-6.004-5.605-0.399
5Y-15.956-8.376-7.580
10Y-9.519-8.865-0.654
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Diamedica is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.11 means the investor is paying $2.11 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of DiaMedica Therapeutics Inc:

  • The EOD is 1.821. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.111. Based on the equity, the company is underpriced. +1
  • The TTM is 2.191. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.821MRQ2.111-0.290
MRQ2.111TTM2.191-0.080
TTM2.191YOY1.897+0.295
TTM2.1915Y7.920-5.728
5Y7.92010Y37.484-29.564
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.8211.896-0.075
MRQ2.1112.115-0.004
TTM2.1912.093+0.098
YOY1.8972.884-0.987
5Y7.9203.542+4.378
10Y37.4843.916+33.568
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of DiaMedica Therapeutics Inc.

3.1. Institutions holding DiaMedica Therapeutics Inc

Institutions are holding 22.018% of the shares of DiaMedica Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Cooperman Leon G2.32790.119588362376300.871
2023-12-31Vanguard Group Inc2.11330.0001802171133821.6965
2023-12-31PARAGON Assoc & PARAGON Assoc II JV1.31723.2569500000300006.383
2023-12-31Altium Capital Management, LP0.75790.5547287698-208302-41.9964
2023-12-31Bleichroeder LP0.58570.140322231700
2023-12-31Geode Capital Management, LLC0.57640.000121877800
2023-09-30Jacob Asset Mgmt Of NY LLC0.44450.6139168730-30000-15.0959
2023-12-31Northern Trust Corp0.35210.00011336334393348.9777
2023-12-31Morgan Stanley - Brokerage Accounts0.318801209952719528.9925
2023-12-31First Manhattan Co. LLC0.30230.001111474400
2023-12-31Aristides Capital LLC0.28010.110310633300
2023-12-31BlackRock Inc0.2759010473230072.956
2023-12-31State Street Corporation0.175506662900
2023-12-31CATALYST FINANCIAL PARTNERS LLC0.09550.02913626700
2023-12-31Bank of New York Mellon Corp0.0902034233-384-1.1093
2023-12-31Millennium Management LLC0.0760288451730.6034
2023-12-31Susquehanna International Group, LLP0.0728027619276190
2023-12-31JANE STREET GROUP, LLC0.0626023761237610
2023-12-31Stonebridge Capital Advisors LLC0.05270.00572000000
2023-12-31Dimensional Fund Advisors, Inc.0.044701695900
Total 10.32214.83183918067-61986-1.6%

3.2. Funds holding DiaMedica Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv1.88520.000171557100
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.65790.000724972519230.776
2023-12-31Jacob Discovery Fd Instl0.41552.2147157730-21000-11.7496
2024-02-29Fidelity Extended Market Index0.30450.0009115564-560-0.4822
2024-03-28iShares Micro-Cap ETF0.1370.01575199900
2023-09-30BlackRock Extended Mkt Composite0.11980.000845461444774520.0203
2024-02-29Fidelity Nasdaq Composite Index0.11260.00084274000
2024-03-31BlackRock Extended Equity Market K0.10450.000839675140.0353
2024-02-29Vanguard Balanced Index Inv0.06470.00012455400
2024-02-29Fidelity Series Total Market Index0.06420.00012435300
2024-02-29Fidelity Total Market Index0.05820.00012209700
2023-12-31Northern Small Cap Core K0.05480.01282081000
2023-12-31NT Ext Equity Mkt Idx Fd - L0.05420.0012058600
2023-12-31Northern Trust Extended Eq Market Idx0.05420.0012058600
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.04150.000115764-490507-96.8863
2024-02-29Vanguard Instl Ttl Stk Mkt Idx InstlPls0.04150.00011576400
2024-02-29Schwab Total Stock Market Index0.03490.00021325100
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.03290.00061248900
2024-02-29Spartan Total Market Index Pool E0.02720.00011031400
2023-12-31NT Quality Small Cap Core0.02660.01210102-1037-9.3096
Total 4.29192.26271629135-466690-28.6%

3.3. Insider Transactions

Insiders are holding 26.706% of the shares of DiaMedica Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-06-23David J WambekeBUY383643.91
2023-06-23Dietrich John PaulsBUY127873.91
2023-06-23Koch Thomas VonBUY14705883.4
2023-06-23Randall Michael GiuffreBUY650003.91
2023-06-23Scott KellenBUY100003.91
2023-04-10David J WambekeBUY4687501.6

4. Summary

4.1. Key Performance Indicators

The key performance indicators of DiaMedica Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.1200.127-195%-0.080-33%0.045-369%0.033-468%
Book Value Per Share--1.3451.274+6%0.958+40%0.786+71%0.406+231%
Current Ratio--19.26618.266+5%23.535-18%18.113+6%10.170+89%
Debt To Asset Ratio--0.0570.061-6%0.050+14%0.070-18%1.163-95%
Debt To Equity Ratio--0.0610.066-7%0.053+14%0.076-20%5.825-99%
Dividend Per Share---0.244-100%-0%0.049-100%0.024-100%
Eps---0.136-0.128-6%-0.090-34%-0.092-33%-0.063-53%
Free Cash Flow Per Share---0.094-0.122+29%-0.076-19%-0.080-15%-0.052-45%
Free Cash Flow To Equity Per Share---0.1070.117-191%-0.076-29%0.046-335%0.032-431%
Gross Profit Margin--1.0021.000+0%1.000+0%1.000+0%1.000+0%
Intrinsic Value_10Y_max---2.556--------
Intrinsic Value_10Y_min---3.942--------
Intrinsic Value_1Y_max---0.214--------
Intrinsic Value_1Y_min---0.379--------
Intrinsic Value_3Y_max---0.676--------
Intrinsic Value_3Y_min---1.158--------
Intrinsic Value_5Y_max---1.176--------
Intrinsic Value_5Y_min---1.955--------
Market Cap92997100.000-16%107800720.000106946665.000+1%69653878.950+55%152743181.790-29%83223674.160+30%
Net Profit Margin----0%-74.6390%-14.9280%-0.2300%
Operating Margin----0%-74.9820%-14.9960%8.814-100%
Operating Ratio----0%149.964-100%29.993-100%3.584-100%
Pb Ratio1.821-16%2.1112.191-4%1.897+11%7.920-73%37.484-94%
Pe Ratio-4.505+14%-5.222-5.652+8%-5.079-3%-11.684+124%-8.208+57%
Price Per Share2.450-16%2.8402.818+1%1.835+55%4.024-29%2.193+30%
Price To Free Cash Flow Ratio-6.490+14%-7.523-5.902-22%-6.004-20%-15.956+112%-9.519+27%
Price To Total Gains Ratio-20.341+14%-23.578-14.279-39%-22.640-4%-42.091+79%-39.942+69%
Quick Ratio--36.47434.155+7%44.297-18%32.291+13%17.224+112%
Return On Assets---0.095-0.105+10%-0.090-5%-0.137+44%-0.512+437%
Return On Equity---0.101-0.113+12%-0.095-6%-0.149+48%-6.776+6603%
Total Gains Per Share---0.1200.370-133%-0.080-33%0.094-229%0.057-311%
Usd Book Value--51057000.00048362750.000+6%36347250.000+40%29832750.000+71%15407318.966+231%
Usd Book Value Change Per Share---0.1200.127-195%-0.080-33%0.045-369%0.033-468%
Usd Book Value Per Share--1.3451.274+6%0.958+40%0.786+71%0.406+231%
Usd Dividend Per Share---0.244-100%-0%0.049-100%0.024-100%
Usd Eps---0.136-0.128-6%-0.090-34%-0.092-33%-0.063-53%
Usd Free Cash Flow---3582487.500-4629871.875+29%-2898000.000-19%-3036074.375-15%-1964362.837-45%
Usd Free Cash Flow Per Share---0.094-0.122+29%-0.076-19%-0.080-15%-0.052-45%
Usd Free Cash Flow To Equity Per Share---0.1070.117-191%-0.076-29%0.046-335%0.032-431%
Usd Market Cap92997100.000-16%107800720.000106946665.000+1%69653878.950+55%152743181.790-29%83223674.160+30%
Usd Price Per Share2.450-16%2.8402.818+1%1.835+55%4.024-29%2.193+30%
Usd Profit---5161000.000-4845250.000-6%-3419000.000-34%-3479500.000-33%-2205102.306-57%
Usd Revenue----0%22250.000-100%4450.000-100%14725.000-100%
Usd Total Gains Per Share---0.1200.370-133%-0.080-33%0.094-229%0.057-311%
 EOD+3 -5MRQTTM+18 -14YOY+10 -225Y+14 -2010Y+16 -19

4.2. Fundamental Score

Let's check the fundamental score of DiaMedica Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.505
Price to Book Ratio (EOD)Between0-11.821
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than136.474
Current Ratio (MRQ)Greater than119.266
Debt to Asset Ratio (MRQ)Less than10.057
Debt to Equity Ratio (MRQ)Less than10.061
Return on Equity (MRQ)Greater than0.15-0.101
Return on Assets (MRQ)Greater than0.05-0.095
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of DiaMedica Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2.540
Total1/1 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -7445-29-34-63-64-1271336



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets54,160
Total Liabilities3,103
Total Stockholder Equity51,057
 As reported
Total Liabilities 3,103
Total Stockholder Equity+ 51,057
Total Assets = 54,160

Assets

Total Assets54,160
Total Current Assets53,675
Long-term Assets485
Total Current Assets
Cash And Cash Equivalents 4,543
Short-term Investments 48,352
Net Receivables 369
Other Current Assets 411
Total Current Assets  (as reported)53,675
Total Current Assets  (calculated)53,675
+/-0
Long-term Assets
Property Plant Equipment 485
Long-term Assets Other 0
Long-term Assets  (as reported)485
Long-term Assets  (calculated)485
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,786
Long-term Liabilities317
Total Stockholder Equity51,057
Total Current Liabilities
Short-term Debt 83
Accounts payable 926
Other Current Liabilities 1,777
Total Current Liabilities  (as reported)2,786
Total Current Liabilities  (calculated)2,786
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt317
Long-term Liabilities  (as reported)317
Long-term Liabilities  (calculated)317
+/-0
Total Stockholder Equity
Retained Earnings -115,558
Accumulated Other Comprehensive Income 6
Other Stockholders Equity 166,609
Total Stockholder Equity (as reported)51,057
Total Stockholder Equity (calculated)51,057
+/-0
Other
Cash and Short Term Investments 52,895
Common Stock Shares Outstanding 37,958
Liabilities and Stockholders Equity 54,160
Net Debt -4,143
Net Invested Capital 51,057
Net Working Capital 50,889
Property Plant and Equipment Gross 585
Short Long Term Debt Total 400



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-31
> Total Assets 
0
0
0
563
0
0
578
707
4,807
4,903
4,612
4,337
4,083
3,539
3,989
2,998
2,369
2,007
1,720
1,245
1,168
9,353
7,232
9,077
8,038
6,767
7,950
6,327
5,281
6,528
5,967
3,847
5,272
2,494
1,485
2,906
1,882
1,722
697
282
315
530
199
222
385
431
3,114
1,873
1,069
1,957
1,024
1,802
7,900
6,386
5,422
18,339
15,494
12,797
11,039
9,053
14,365
12,581
31,270
28,095
24,356
21,774
48,664
45,551
42,211
39,258
37,041
34,395
30,217
62,050
58,139
54,160
54,16058,13962,05030,21734,39537,04139,25842,21145,55148,66421,77424,35628,09531,27012,58114,3659,05311,03912,79715,49418,3395,4226,3867,9001,8021,0241,9571,0691,8733,1144313852221995303152826971,7221,8822,9061,4852,4945,2723,8475,9676,5285,2816,3277,9506,7678,0389,0777,2329,3531,1681,2451,7202,0072,3692,9983,9893,5394,0834,3374,6124,9034,80770757800563000
   > Total Current Assets 
0
0
0
318
0
0
234
337
4,389
4,365
3,944
3,647
3,402
2,812
3,278
2,541
1,930
1,508
1,179
695
633
2,384
618
3,142
2,530
1,846
3,896
2,736
2,190
4,044
3,988
2,465
4,464
2,239
1,190
2,617
1,587
1,407
680
266
302
516
186
208
372
416
3,097
1,854
1,051
1,936
1,000
1,494
7,568
6,056
5,081
17,972
14,944
12,276
10,806
8,836
14,165
12,399
31,106
27,921
24,195
21,629
48,537
45,439
42,111
39,173
36,490
33,835
29,674
41,231
47,886
53,675
53,67547,88641,23129,67433,83536,49039,17342,11145,43948,53721,62924,19527,92131,10612,39914,1658,83610,80612,27614,94417,9725,0816,0567,5681,4941,0001,9361,0511,8543,0974163722081865163022666801,4071,5872,6171,1902,2394,4642,4653,9884,0442,1902,7363,8961,8462,5303,1426182,3846336951,1791,5081,9302,5413,2782,8123,4023,6473,9444,3654,38933723400318000
       Cash And Cash Equivalents 
0
0
0
275
0
0
197
270
4,230
4,237
3,743
3,502
3,347
2,707
3,163
2,468
1,892
1,443
1,079
630
338
156
482
2,837
2,403
1,775
3,852
2,652
2,075
3,917
3,885
2,340
4,338
2,080
1,065
2,521
1,471
1,249
486
204
268
458
140
166
333
365
2,964
1,736
939
1,530
858
1,353
6,719
5,661
3,901
16,823
2,759
2,974
4,741
3,883
3,300
4,955
9,797
7,409
3,329
2,228
16,219
4,707
3,032
3,062
2,771
4,728
2,147
5,839
2,232
4,543
4,5432,2325,8392,1474,7282,7713,0623,0324,70716,2192,2283,3297,4099,7974,9553,3003,8834,7412,9742,75916,8233,9015,6616,7191,3538581,5309391,7362,9643653331661404582682044861,2491,4712,5211,0652,0804,3382,3403,8853,9172,0752,6523,8521,7752,4032,8374821563386301,0791,4431,8922,4683,1632,7073,3473,5023,7434,2374,23027019700275000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,958
7,992
5,002
3,995
9,348
6,844
20,826
20,098
20,072
19,067
31,878
40,405
38,015
35,381
33,313
28,774
26,508
34,529
44,233
48,352
48,35244,23334,52926,50828,77433,31335,38138,01540,40531,87819,06720,07220,09820,8266,8449,3483,9955,0027,99210,95800000000000000000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
30
0
0
26
57
150
105
182
96
38
70
94
31
18
38
76
48
198
2,193
119
221
38
45
26
50
74
32
20
21
35
46
24
14
55
77
77
8
10
13
7
10
14
17
51
52
60
348
67
80
800
285
1,019
780
929
1,112
664
823
985
319
335
340
337
16
104
130
168
88
75
82
57
188
310
369
36931018857827588168130104163373403353199858236641,1129297801,01928580080673486052511714107131087777551424463521203274502645382211192,19319848763818319470389618210515057260030000
       Other Current Assets 
0
0
0
13
0
0
10
10
9
22
19
50
17
35
21
42
20
27
24
17
97
35
17
84
88
26
18
34
42
95
82
104
92
113
101
82
62
81
117
54
23
45
39
33
25
34
83
65
53
58
75
61
50
110
161
369
298
198
89
47
337
235
138
64
457
318
336
84
793
534
322
251
1,019
863
1,111
411
4111,1118631,0192513225347938433631845764138235337478919829836916111050617558536583342533394523541178162821011139210482954234182688841735971724272042213517501922910100013000
   > Long-term Assets 
0
0
0
244
0
0
345
370
418
538
668
690
681
727
711
457
439
500
541
551
535
6,970
6,614
5,936
5,509
4,921
4,054
3,591
3,091
2,484
1,979
1,383
808
255
294
289
295
315
16
16
14
14
13
14
13
15
17
19
19
21
24
308
332
330
341
367
550
521
233
217
200
182
164
174
161
145
127
112
100
85
551
560
543
20,819
10,253
485
48510,25320,81954356055185100112127145161174164182200217233521550367341330332308242119191715131413141416163152952892942558081,3831,9792,4843,0913,5914,0544,9215,5095,9366,6146,97053555154150043945771172768169066853841837034500244000
       Property Plant Equipment 
0
0
0
16
0
0
14
13
13
75
157
154
141
135
122
100
92
92
93
88
86
30
32
9
9
8
7
7
7
7
7
7
20
20
19
20
18
17
16
16
14
14
13
14
13
15
17
19
19
21
24
37
65
73
91
96
279
250
233
217
200
182
164
174
161
145
127
112
100
85
551
560
543
523
507
485
4855075235435605518510011212714516117416418220021723325027996917365372421191917151314131414161617182019202077777789932308688939292100122135141154157751313140016000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20,296
9,746
0
09,74620,2960000000000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
228
0
0
330
357
405
463
510
536
540
592
589
357
348
408
448
463
450
6,939
6,582
5,927
5,500
4,913
4,047
3,587
3,084
2,476
1,972
1,376
788
235
275
269
276
298
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000002982762692752357881,3761,9722,4763,0843,5874,0474,9135,5005,9276,5826,93945046344840834835758959254053651046340535733000228000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,946
0
4,940
0
0
3,106
2,477
1,976
1,379
789
235
0
0
277
298
0
0
0
0
0
0
0
0
0
0
0
0
0
269
42
257
251
271
271
271
0
0
0
0
0
100
0
0
0
0
0
0
0
0
0
0
0
0
00000000000010000000271271271251257422690000000000000298277002357891,3791,9762,4773,106004,94005,94600000000000000000000000
> Total Liabilities 
0
0
0
56
0
0
59
53
154
394
102
272
303
331
249
218
260
59
179
198
553
1,209
174
554
553
537
475
365
756
935
820
1,582
1,688
905
963
1,525
2,280
1,636
1,408
1,810
1,693
1,470
1,345
1,452
1,398
1,471
1,496
627
1,064
1,225
1,055
1,003
3,167
4,921
4,079
1,314
1,588
1,095
1,339
1,436
1,042
1,309
1,512
2,081
1,211
1,456
1,628
1,527
1,443
1,543
1,962
2,568
3,195
2,307
2,510
3,103
3,1032,5102,3073,1952,5681,9621,5431,4431,5271,6281,4561,2112,0811,5121,3091,0421,4361,3391,0951,5881,3144,0794,9213,1671,0031,0551,2251,0646271,4961,4711,3981,4521,3451,4701,6931,8101,4081,6362,2801,5259639051,6881,5828209357563654755375535541741,2095531981795926021824933130327210239415453590056000
   > Total Current Liabilities 
0
0
0
56
0
0
59
53
154
394
102
272
303
331
249
218
260
59
179
198
553
1,209
174
554
553
537
475
365
756
935
820
1,582
1,688
905
963
1,525
2,280
1,636
1,408
1,810
674
585
888
1,064
987
1,471
1,496
627
1,064
1,019
675
1,003
1,106
1,239
1,459
1,296
1,425
947
1,205
1,318
935
1,217
1,443
2,028
1,178
1,440
1,624
1,524
1,434
1,536
1,542
2,168
2,814
1,946
2,170
2,786
2,7862,1701,9462,8142,1681,5421,5361,4341,5241,6241,4401,1782,0281,4431,2179351,3181,2059471,4251,2961,4591,2391,1061,0036751,0191,0646271,4961,4719871,0648885856741,8101,4081,6362,2801,5259639051,6881,5828209357563654755375535541741,2095531981795926021824933130327210239415453590056000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
190
0
0
0
0
0
0
0
0
0
0
0
5
54
55
56
60
56
56
65
65
69
69
64
49
34
18
41
69
78
79
80
83
83807978694118344964696965655656605655545000000000001900000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
190
0
0
0
0
0
0
0
0
0
0
0
0
49
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000490000000000001900000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
56
0
0
59
53
154
394
102
272
303
331
249
0
0
0
0
0
0
0
0
58
232
131
263
139
431
692
449
1,192
1,241
368
318
372
193
376
352
960
247
271
565
672
592
992
1,051
327
541
554
525
513
637
586
401
483
685
262
312
182
444
552
720
1,099
689
239
699
509
433
624
864
734
1,780
856
863
926
9268638561,7807348646244335096992396891,0997205524441823122626854834015866375135255545413271,0519925926725652712479603523761933723183681,2411,192449692431139263131232580000000024933130327210239415453590056000
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
218
260
59
179
198
553
1,209
174
554
321
406
212
365
756
242
371
391
447
537
645
1,152
2,087
1,260
1,056
850
427
314
323
358
369
463
439
300
523
465
149
490
469
653
1,058
774
49
590
805
1,024
417
586
645
856
413
1,125
838
966
967
894
637
1,365
956
1,011
1,227
1,777
1,7771,2271,0119561,3656378949679668381,1254138566455864171,024805590497741,0586534694901494655233004394633693583233144278501,0561,2602,0871,1526455374473913712427563652124063215541741,20955319817959260218000000000000000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,019
885
457
388
411
0
0
0
0
206
380
0
2,061
3,683
2,619
18
163
148
134
118
107
92
69
53
33
16
4
3
9
7
420
400
381
361
340
317
31734036138140042079341633536992107118134148163182,6193,6832,061038020600004113884578851,0190000000000000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18
17
15
14
13
11
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000001113141517180000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
426
389
411
0
0
0
0
207
381
113
328
3,683
2,619
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000002,6193,6833281133812070000411389426000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
506
0
0
519
654
4,653
4,509
4,510
4,065
3,780
3,207
3,740
2,780
2,109
1,948
1,541
1,048
615
8,145
7,058
8,523
7,485
6,231
7,475
5,962
4,525
5,594
5,147
2,265
3,584
1,589
522
1,382
-398
86
-711
-1,529
-1,378
-940
-1,146
-1,230
-1,014
-1,040
1,618
1,246
5
732
-31
799
4,733
1,465
1,343
17,025
13,906
11,702
9,700
7,617
13,323
11,272
29,758
26,014
23,145
20,318
47,036
44,024
40,768
37,715
35,079
31,827
27,022
59,743
55,629
51,057
51,05755,62959,74327,02231,82735,07937,71540,76844,02447,03620,31823,14526,01429,75811,27213,3237,6179,70011,70213,90617,0251,3431,4654,733799-3173251,2461,618-1,040-1,014-1,230-1,146-940-1,378-1,529-71186-3981,3825221,5893,5842,2655,1475,5944,5255,9627,4756,2317,4858,5237,0588,1456151,0481,5411,9482,1092,7803,7403,2073,7804,0654,5104,5094,65365451900506000
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21,615
22,436
22,705
23,228
23,921
24,703
27,692
30,663
30,357
33,031
32,072
32,681
33,576
32,478
35,104
33,449
32,234
29,936
30,967
29,055
28,155
30,384
31,130
34,195
40,994
41,005
42,723
42,723
44,238
48,943
49,030
49,087
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000049,08749,03048,94344,23842,72342,72341,00540,99434,19531,13030,38428,15529,05530,96729,93632,23433,44935,10432,47833,57632,68132,07233,03130,35730,66327,69224,70323,92123,22822,70522,43621,61500000000000000000000000
   Retained Earnings Total Equity00-105,926-101,449000000-75,805-72,531-68,909-64,709-61,516-59,042-56,617-54,137-51,689-49,220-45,9680000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-20
0
0
-23
-23
-24
-27
-34
91
88
89
86
-57
-61
-73
-86
-95
-102
-53
-57
-8
-9
-10
-10
-11
-12
-12
-13
-16
-17
-17
-19
-19
-19
-21
-21
-20
-21
-22
-21
-21
-22
-23
-23
587
603
616
600
611
584
498
580
-24
3
11
6
2
42
29
10
-2
-4
-3
-5
-51
-107
-167
-162
-74
-29
-63
-127
6
6-127-63-29-74-162-167-107-51-5-3-4-210294226113-24580498584611600616603587-23-23-22-21-21-22-21-20-21-21-19-19-19-17-17-16-13-12-12-11-10-10-9-8-57-53-102-95-86-73-61-5786898891-34-27-24-23-2300-20000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,671
6,963
7,231
62,993
63,123
63,380
63,831
64,232
72,323
72,759
94,457
94,925
95,680
96,126
0
0
0
0
0
0
128,500
165,732
0
0
00165,732128,50000000096,12695,68094,92594,45772,75972,32364,23263,83163,38063,12362,9937,2316,9636,6710000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
2,776
0
0
3,470
3,696
7,894
9,036
9,785
9,861
9,548
9,685
10,682
9,482
9,219
10,151
11,059
11,301
11,613
19,456
19,795
23,432
24,427
24,749
26,520
27,161
28,050
31,222
34,210
34,077
37,417
36,470
37,416
38,520
37,410
40,485
38,786
37,356
34,673
36,216
33,445
32,746
35,659
36,283
39,288
6,373
6,413
6,480
6,630
40,422
6,671
6,963
7,231
63,017
63,123
63,380
63,831
64,232
72,323
72,759
94,457
94,925
95,680
96,126
126,296
126,576
126,884
127,249
127,667
128,078
128,500
165,732
166,153
166,609
166,609166,153165,732128,500128,078127,667127,249126,884126,576126,29696,12695,68094,92594,45772,75972,32364,23263,83163,38063,12363,0177,2316,9636,67140,4226,6306,4806,4136,37339,28836,28335,65932,74633,44536,21634,67337,35638,78640,48537,41038,52037,41636,47037,41734,07734,21031,22228,05027,16126,52024,74924,42723,43219,79519,45611,61311,30111,05910,1519,2199,48210,6829,6859,5489,8619,7859,0367,8943,6963,470002,776000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-30
Gross Profit-30-30
 
Operating Income (+$)
Gross Profit-30
Operating Expense-21,237
Operating Income-21,267-21,267
 
Operating Expense (+$)
Research Development13,110
Selling General Administrative8,157
Selling And Marketing Expenses30
Operating Expense21,23721,297
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-21,267
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-19,338-23,196
EBIT - interestExpense = -21,267
-19,338
-19,381
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-21,267-19,338
Earnings Before Interest and Taxes (EBITDA)-21,237
 
After tax Income (+$)
Income Before Tax-19,338
Tax Provision-28
Net Income From Continuing Ops-17,971-19,366
Net Income-19,381
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses21,267
Total Other Income/Expenses Net1,9290
 

Technical Analysis of Diamedica
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Diamedica. The general trend of Diamedica is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Diamedica's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of DiaMedica Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 2.55 < 2.57 < 3.2.

The bearish price targets are: 2.3431 > 2.12 > 2.05.

Tweet this
DiaMedica Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of DiaMedica Therapeutics Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

DiaMedica Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartDiaMedica Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of DiaMedica Therapeutics Inc. The current adx is .

DiaMedica Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc Daily Relative Strength Index (RSI) ChartDiaMedica Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc Daily Stochastic Oscillator ChartDiaMedica Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc Daily Commodity Channel Index (CCI) ChartDiaMedica Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartDiaMedica Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc Daily Williams %R ChartDiaMedica Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc Daily Average True Range (ATR) ChartDiaMedica Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc Daily On-Balance Volume (OBV) ChartDiaMedica Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc Daily Money Flow Index (MFI) ChartDiaMedica Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for DiaMedica Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

DiaMedica Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of DiaMedica Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2.540
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Diamedica with someone you think should read this too:
  • Are you bullish or bearish on Diamedica? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Diamedica? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about DiaMedica Therapeutics Inc

I send you an email if I find something interesting about DiaMedica Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about DiaMedica Therapeutics Inc.

Receive notifications about DiaMedica Therapeutics Inc in your mailbox!